)
An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
A potential breakthrough in cardiovascular medicine has emerged with the development of lepodisiran, an experimental drug by pharmaceutical company Eli Lilly. The drug has demonstrated an unprecedented ability to lower levels of lipoprotein(a), or Lp(a), a …